{"title":"百特通过授权Onconova Therapeutics的Rigosertib的欧洲权利扩大其肿瘤产品线","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I9.1811","DOIUrl":null,"url":null,"abstract":"In return for US$50 M upfront and up to US$515 M in precommercialisation milestone payments, Baxter International has licensed European commercialisation rights to Onconova Therapeutics’ lead anticancer therapy rigosertib. The drug candidate is currently in Phase III development for myelodysplastic syndromes, for which it has been granted Orphan Drug Designation in the US and Europe, and is the subject of a Phase II/III study in pancreatic cancer. Baxter, which has an existing US$50 M equity position in Onconova, also has the option to develop rigosertib in additional indications.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"50 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Baxter Expands its Oncology Pipeline by Licensing European Rights to Onconova Therapeutics’ Rigosertib\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I9.1811\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In return for US$50 M upfront and up to US$515 M in precommercialisation milestone payments, Baxter International has licensed European commercialisation rights to Onconova Therapeutics’ lead anticancer therapy rigosertib. The drug candidate is currently in Phase III development for myelodysplastic syndromes, for which it has been granted Orphan Drug Designation in the US and Europe, and is the subject of a Phase II/III study in pancreatic cancer. Baxter, which has an existing US$50 M equity position in Onconova, also has the option to develop rigosertib in additional indications.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"50 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I9.1811\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I9.1811","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Baxter Expands its Oncology Pipeline by Licensing European Rights to Onconova Therapeutics’ Rigosertib
In return for US$50 M upfront and up to US$515 M in precommercialisation milestone payments, Baxter International has licensed European commercialisation rights to Onconova Therapeutics’ lead anticancer therapy rigosertib. The drug candidate is currently in Phase III development for myelodysplastic syndromes, for which it has been granted Orphan Drug Designation in the US and Europe, and is the subject of a Phase II/III study in pancreatic cancer. Baxter, which has an existing US$50 M equity position in Onconova, also has the option to develop rigosertib in additional indications.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
